Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
As investors rotate toward value, Altria, Bristol Myers Squibb, and American Electric Power stand out as reliable dividend stocks with strong payout growth histories and defensive appeal.
Kimmtrak anchors IMCR today, but its broader T-cell receptor platform is targeting larger cancer, infectious disease and autoimmune markets.
Kimmtrak's sales growth supports IMCR, but premium valuation and reliance on one product keep investors focused on upcoming pipeline catalysts.
IMCR's Kimmtrak sales climbed 29% in 2025 on wider adoption, with pivotal 2026 trial results set to test its next expansion opportunity.
Evaluate the expected performance of Bristol Myers (BMY) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Analysts aren't nearly as bullish about Bristol Myers Squibb as this billionaire hedge fund manager is.
In July 2026, Agilent Technologies received U.S. Food and Drug Administration approval for its PD-L1 IHC 28-8 pharmDx assay as a companion diagnostic to identify patients with several gastric and esophageal cancers who may be eligible for treatment with Bristol Myers Squibb’s OPDIVO and OPDIVO QVANTIG, for use exclusively on the Agilent Autostainer Link 48 platform. This approval deepens Agilent’s role in immuno-oncology testing by tying its assay directly to widely used PD-1 therapies in...
Sometimes you need to look beyond the numbers to get the full story.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 9.7% gain over the past six months, beating the S&P 500 by 1.8 percentage points.
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $61.4, denoting a +1.05% move from the preceding trading day.
Revolution Medicines' FDA filing for daraxonrasib in metastatic pancreatic cancer enters an accelerated review program, bringing its first commercial product closer.
Bristol Myers (BMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bank of America is breaking with the Fed's wait-and-see approach and pushing for rate hikes now, which reshuffles the entire investing playbook. Four dividend-paying stocks across the sectors that quietly thrive when borrowing costs climb deserve a closer look.
Keytruda is expected to drive another strong quarter for MRK, with investors watching Q2 sales and management's outlook ahead of the drug's 2028 patent expiry.
Alexandria Real Estate Equities (NYSE:ARE) has delivered a 427,000 RSF research and development facility for Bristol Myers Squibb at its San Diego megacampus. The new state-of-the-art R&D hub marks an operational milestone for the company and reflects demand from a large multinational pharmaceutical tenant. Alexandria Real Estate Equities focuses on life science and R&D campuses that serve large pharmaceutical and biotech companies. The new San Diego facility for Bristol Myers Squibb adds...
Bristol Myers Squibb (NYSE:BMY) is rolling out new AI infrastructure built on NVIDIA's latest architecture to support drug discovery. The company is applying this technology across oncology, cardiovascular disease and other core therapeutic areas. Bristol Myers Squibb has opened a 427,000 square foot R&D hub at the Campus Point Megacampus in San Diego. The new site is intended to bring together research teams and laboratory capacity in a single large West Coast center. Bristol Myers Squibb...
Pfizer's non-oncology portfolio faced mixed Q2 trends. Eliquis and Vyndaqel sales may have risen while COVID products will have declined.
BMS enhances its AI computing power as big pharma race to stay competitive within the shifting global landscape.
Drugmaker deploys NVIDIA DGX SuperPOD with Vera Rubin systems to accelerate medicine discovery.
Healthcare stocks declined late Monday afternoon, with the NYSE Healthcare Index shedding 1.1% and t
The drugmaker will deploy NVIDIA's Vera Rubin systems, giving it what it calls the most powerful AI computing infrastructure in life sciences
Bristol Myers Squibb (NYSE:BMY) has expanded its artificial intelligence collaboration with Nvidia (NASDAQ:NVDA), announcing plans to deploy an Nvidia DGX SuperPOD powered by DGX Vera Rubin NVL72 systems to strengthen its AI infrastructure for drug discovery and development. The expansion builds on a partnership that began nearly three years ago and is designed to provide significantly greater computing power for AI-driven research.
For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as Merck Keytruda, the best-selling drug in the world. Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form of bispecific antibodies. Bispecific antibodies are being tested by Bristol Myers Squibb (with its partner BioNTech ), AstraZeneca and the biotech firm Summit Therapeutics ADCs have already rung up big sales for Astra, Pfizer Gilead Sciences and Roche Holding but Merck has a strong contender in development.
Bristol Myers Squibb said on Monday it is buying the latest-generation computing system from chip company Nvidia to support its use of artificial intelligence across its drug discovery and development operations. The drugmaker said it will be the first life sciences company to buy an Nvidia DGX SuperPOD based on its Vera Rubin systems. The chipmaker unveiled its Vera Rubin architecture earlier this year as the successor to its current generation of AI computing systems.
Bristol Myers is the third pharmaceutical company to recently seek Nvidia’s help building a large AI data center. Elsewhere, a Novartis kidney drug gained a leg up on competitors.
For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as Merck Keytruda, the best-selling drug in the world. Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form of bispecific antibodies. Bispecific antibodies are being tested by Bristol Myers Squibb (with its partner BioNTech ), AstraZeneca and the biotech firm Summit Therapeutics ADCs have already rung up big sales for Astra, Pfizer Gilead Sciences and Roche Holding but Merck has a strong contender in development.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
